Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

n, of which $8.5 million was related to cost sharing and $18.1 million was related to the Excess Amounts, which are due to be received during our quarter ending March 31, 2013. At June 30, 2012, the Company had $5.8 million due from Janssen related to cost sharing. At September 30, 2012, the Company had cash, cash equivalents and marketable securities of $286.1 million.

The Company expects to end calendar year 2013 with cash, cash equivalents and marketable securities of more than $225 million.

"Ibrutinib has demonstrated great clinical progress during this past year. Today we have a very solid development program in place with 5 Phase III trials initiated and several more trials to be started this year. We were honored to announce this past Tuesday that ibrutinib received Breakthrough Designation in two B-cell malignancies. We look forward to working with the FDA to bring this therapy to market in a timely manner," said Bob Duggan, CEO and Chairman of the Board. "Looking ahead, our goals for this year are star high as we are continuing to unfold our clinical program. With our partner Janssen, we are committed to a shared vision of patient friendly, body harmonious solutions intended to improve the quality of life, increase duration of life and resolve serious medical health care needs for patients."

Recent Developments & HighlightsBreakthrough Therapy Designation

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act.

Pharmacyclics, together
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... BLOOMINGTON, Ind. -- Chemists at Indiana University Bloomington ... in bricks-and-mortar fashion, a development with potential value ... as field-effect transistors and photovoltaic cells. , Their ... 3D Crystalline Solids and 2D Self-Assembled Crystals," has ... a journal of the Royal Society of Chemistry. ...
(Date:7/31/2014)... Graphite Metallizing Corporation announces GRAPHALLOY® bearings ... are uniquely suited to prevent loss of lubrication that ... high temperatures . , Recently, a manufacturer of ... at Graphite Metallizing to overcome problems with movement of ... pans containing blocks of powder mixture are loaded onto ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 CollabRx, Inc. ... inform therapeutic decision-making in oncology, today announced that it ... 2014 to discuss the Company's financial results for the ... update about the business in the current fiscal year. ... beginning on Thursday, August 14, 2014, at 5 p.m. ...
(Date:7/31/2014)... Francisco, Calif. (PRWEB) July 31, 2014 ... newly diagnosed patients with an overview of the disease ... management of drug side effects, as well as updates ... “We’re grateful to Dr. Sandy Srinivas for organizing this ... survivor of kidney cancer. “Sandy and her colleagues have ...
Breaking Biology Technology:Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... deCODE genetics,(Nasdaq: DCGN ) today announced its ... 2008. A conference call to discuss the,quarter,s results, ... webcast live tomorrow, Friday, November 7, at 8:00am ... third quarter 2008 was $11.3 million, compared,to $22.2 ...
... NGX-4010 for management of pain associated ... with PHN, ... review for NGX-4010 ... NGSX ), a biopharmaceutical company focused on developing and,commercializing novel pain management ...
... While Public Relations has,long been used as a ... ability to reach consumers has never been greater. ... the traditional press,release as effective and low-cost methods ... was conducted by Best Practices, LLC to,identify what ...
Cached Biology Technology:deCODE genetics Announces Third Quarter 2008 Financial Results 2deCODE genetics Announces Third Quarter 2008 Financial Results 3deCODE genetics Announces Third Quarter 2008 Financial Results 4deCODE genetics Announces Third Quarter 2008 Financial Results 5deCODE genetics Announces Third Quarter 2008 Financial Results 6deCODE genetics Announces Third Quarter 2008 Financial Results 7deCODE genetics Announces Third Quarter 2008 Financial Results 8deCODE genetics Announces Third Quarter 2008 Financial Results 9deCODE genetics Announces Third Quarter 2008 Financial Results 10deCODE genetics Announces Third Quarter 2008 Financial Results 11deCODE genetics Announces Third Quarter 2008 Financial Results 12NeurogesX Reports Third Quarter 2008 Results 2NeurogesX Reports Third Quarter 2008 Results 3NeurogesX Reports Third Quarter 2008 Results 4NeurogesX Reports Third Quarter 2008 Results 5NeurogesX Reports Third Quarter 2008 Results 6NeurogesX Reports Third Quarter 2008 Results 7NeurogesX Reports Third Quarter 2008 Results 8NeurogesX Reports Third Quarter 2008 Results 9New Study Shares Best Practices in Biopharma Public Relations 2
(Date:7/31/2014)... adipocytes, or fat cells, are inherently different. Each of ... its own role in metabolism. In the human body, ... Its primary function is energy storage. On the other ... but are only found in a few places in ... special type of brown adipocytes, appear mixed with brown ...
(Date:7/31/2014)... studies have shown that marine noise can affect animal ... the Universities of Bristol and Exeter and the cole ... demonstrated that boat noise stops embryonic development and increases ... the sea slug Stylocheilus striatus used in ... away and later feed on toxic alga but this ...
(Date:7/30/2014)... epigenetic processes to regulate its genes, and adapt to ... of the genome regulation taking place in the truffle, ... Biology and illustrates how the truffle deals with ... authors say this may shed light on how traits ... (Tuber melanosporum), also known as Prigord truffles, have a ...
Breaking Biology News(10 mins):Hope for the overweight 2Boat noise impacts development and survival of sea hares 2How black truffles deal with the jumpers in their genome 2
... Fast development is often perceived as an advantage, ... readiness to cope with the challenges that it poses. ... and University of California, Santa Cruz, and published in ... the acceleration of developmental rate incurs potentially lethal physiological ...
... molding some snow into a ball and hurling it or ... can? New research from Indiana University and the University of ... readily learn to throw long distances. This research also suggests ... in a way critical to our very existence. ...
... N.C. Despite what you might have heard, genetic sequencing ... Duke University Medical Center have shown that functional tests are ... of sequencing studies as they relate to disease, using a ... patients to have many different traits. "Right now ...
Cached Biology News:Faster development might have its costs 2Faster development might have its costs 3IU study: Humans' critical ability to throw long distances aided by an illusion 2IU study: Humans' critical ability to throw long distances aided by an illusion 3Genetic sequencing alone doesn't offer a true picture of human disease 2Genetic sequencing alone doesn't offer a true picture of human disease 3
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... Analysis Note: Protein determined by Biuret ... 25 mM Tris-HCl, pH 7.6, 1 mM ... 2 Preparation Unit Definition: One unit ... per minute at pH 9.8 at 37 ...
Biology Products: